Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyBlue Cross Blue Shield NM H. pylori Coverage Updat…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - New MexicoPolicy RPLAB018

    Helicobacter pylori Testing

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - New Mexico Policy RPLAB018 alerts

    Get alerted when Policy RPLAB018 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Reimbursement criteria for diagnostic and post-treatment testing for H. pylori for Blue Cross Blue Shield - New Mexico members; applies to providers submitting claims for laboratory/pathology services under this payer.

    Policy Summary
    PayerBlue Cross Blue Shield - New Mexico
    PolicyHelicobacter pylori Testing
    Policy CodePolicy RPLAB018
    Change TypeCoverage additions and clarifications (material)
    Effective DateSep 4, 2026
    Last ReviewJul 1, 2024
    Next Review Date
    Key ActionProviders must submit accurate documentation and may be asked to provide additional documentation upon request; claims are subject to review.
    SourceLink
    POLICY UPDATE CHANGES

    Urea breath testing or stool antigen testing to document eradication performed at least four weeks post-treatment is included as reimbursable.

    Susceptibility testing (culture or nucleic acid based) is reimbursable for refractory H. pylori infection.

    Clarified and expanded the adult indications list for noninvasive testing (urea breath or stool antigen) including dyspepsia, PUD, MALT lymphoma, gastric intestinal metaplasia, NSAID/aspirin use, unexplained iron deficiency anemia, ITP, family history of gastric cancer, and first-generation immigrants from high prevalence areas.

    Explicit prohibitions: serology for H. pylori is not reimbursable for any age; concurrent multiple-test diagnostic approaches are not reimbursable; testing after recent antibiotics, PPIs, or bismuth is not reimbursable.

    Added CPT code 87513 to the procedure code list.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≥18adult indications
    4 wkspost-treatment interval
    excludedserology coverage
    87513new code

    Coverage and Medical Necessity Criteria

    Coverage criteria — Reimbursable H. pylori testing by age, test type, and clinical scenario

    Covered when the conditions below are met:

    Applies to reimbursement for H. pylori testing as described below.

    Indications Where Testing Is Reimbursable

    Procedure Codes and Frequency Notes

    Representative procedure codes listed in policyCPT
    83009H PYLORI (C-13) BLOOD
    83013H PYLORI (C-13) BREATH
    83014H PYLORI DRUG ADMIN
    86318IA INFECTIOUS AGENT ANTIBODY
    86677HELICOBACTER PYLORI ANTIBODY
    87070CULTURE OTHR SPECIMN AEROBIC
    87077CULTURE AEROBIC IDENTIFY
    87081CULTURE SCREEN ONLY
    87149DNA/RNA DIRECT PROBE
    87150DNA/RNA AMPLIFIED PROBE
    1–10 of 19
    1/2
    inv-03: Post-treatment testing interval (minimum 4 weeks)
    Post-treatment test-of-cure intervalUrea breath testing or stool antigen testing to document eradication must be performed at least 4 weeks after completion of therapy.
    Refractory infection allowanceSusceptibility testing (culture or nucleic acid–based) may be reimbursable for refractory H. pylori infection.
    Nonreimbursable within windowTesting performed while the patient has recent antibiotics, proton pump inhibitors, or bismuth use is not reimbursable for diagnosing H. pylori.

    Ordering, Documentation, and Claim Submission

    Documentation Required

    Documentation, coding, and potential request for additional records

    Providers are responsible for submitting accurate documentation of services performed and should code claims using valid, industry-standard code sets; claims are subject to code edit protocols and review. Upon request, the provider may be asked to submit additional documentation to support the claim.

    • Submit claims using valid code combinations from HIPAA-approved code sets and code appropriately per industry coding guidelines.
    • Claims are subject to code edit protocols and claim review; provide additional documentation upon request.

    Ordering Requirements

    Billing Rule

    Document clinical indication and link orders to endoscopy/biopsy encounters

    Document the clinical indication for H. pylori testing in the medical record; for endoscopic or biopsy-based testing, ordering typically occurs in the setting of endoscopy or for patients with alarm symptoms and should be reflected in the order and documentation.

    • Record the specific clinical scenario (e.g., dyspepsia, active PUD, alarm symptoms) that supports testing.
    • For endoscopic evaluations, ensure the biopsy-based histology request and accompanying rapid urease or culture/susceptibility testing order are documented as part of the endoscopy encounter.

    Services and Situations Not Reimbursable

    Serologic (antibody) testing for Helicobacter pylori is explicitly excluded from reimbursement for individuals of all ages. Providers should not submit claims for H. pylori serology as this test is not reimbursable under this policy.

    Diagnostic testing to detect H. pylori infection is not reimbursable for asymptomatic individuals of any age. Claims for urea breath test, stool antigen, or biopsy-based diagnostic testing submitted for asymptomatic patients will be denied.

    Testing to diagnose H. pylori infection performed within the period of recent antibiotic, proton pump inhibitor (PPI), or bismuth use is not reimbursable. Providers must ensure appropriate medication-free intervals before ordering diagnostic urea breath, stool antigen, or biopsy-based tests.

    Concurrent use of multiple diagnostic modalities—such as performing a urea breath test, stool antigen test, and biopsy-based testing together for initial diagnosis—is not reimbursable. Only a single appropriate diagnostic approach should be used when establishing an initial H. pylori diagnosis.

    Nucleic acid testing for H. pylori is not reimbursable in general. An exception exists for individuals with a refractory H. pylori infection: in that specific context, nucleic acid–based methods used for susceptibility testing (in addition to culture-based susceptibility testing) may be reimbursable.

    In pediatric patients (<18 years), endoscopic biopsy-based testing (histology, rapid urease testing, or culture) to diagnose H. pylori is not reimbursable when performed for functional abdominal pain, as part of the initial evaluation of iron deficiency anemia, or when investigating short stature. Such biopsy-based diagnostic procedures in these listed pediatric-limited indications will not be reimbursed.

    Testing Frequency and Timing

    inv-12: urea breath test or stool antigen (test-of-cure) — minimum interval of at least 4 weeks post-treatment
    Minimum interval for test-of-cureUrea breath test or stool antigen (test-of-cure) must be performed at least four weeks post-treatment to be reimbursable.
    Scope of reimbursable post-treatment testingApplies to all individuals who previously tested positive for H. pylori.
    Concurrent testing prohibitionConcurrent use of multiple diagnostic modalities (UBT, stool antigen, biopsy) for diagnosis is not reimbursable; post-treatment testing should follow the single recommended modality after the 4‑week interval.

    Definitions and Clinical Terms

    inv-05: Dyspepsia definition — bothersome upper abdominal symptoms often meal-related, including postprandial fullness, early satiety, or epigastric pain or burning; chronic dyspepsia more often presents with fullness/satiety than pain
    Definition of dyspepsiaDyspepsia refers to bothersome upper abdominal symptoms often meal‑related, including postprandial fullness, early satiety, or epigastric pain or burning; chronic dyspepsia more often presents with fullness/satiety than pain.
    Meal‑related predominancePredominant symptoms are fullness (bloating) after meals or early satiety (inability to finish a normal-sized meal because of postprandial discomfort).
    Pain not requiredEpigastric pain may or may not be related to meals and is not required to make a diagnosis of dyspepsia.
    inv-06: Alarm features — vomiting, gastrointestinal bleeding, unexplained iron deficiency, or weight loss
    Alarm features listVomiting, gastrointestinal bleeding, unexplained iron deficiency, or weight loss.
    Policy Summary
    PayerBlue Cross Blue Shield - New Mexico
    PolicyHelicobacter pylori Testing
    Policy CodePolicy RPLAB018
    Change TypeCoverage additions and clarifications (material)
    Effective DateSep 4, 2026
    Last ReviewJul 1, 2024
    Next Review Date
    Key ActionProviders must submit accurate documentation and may be asked to provide additional documentation upon request; claims are subject to review.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaIndications Where Testing Is ReimbursableProcedure Codes and Frequency NotesOrdering, Documentation, and Claim SubmissionOrdering RequirementsServices and Situations Not ReimbursableTesting Frequency and TimingDefinitions and Clinical Terms
    Context of useThese alarm features help identify patients who may require endoscopic evaluation rather than routine noninvasive testing.
    Relevance to coveragePresence of alarm features is included in reimbursement considerations for diagnostic approaches in the policy.